Kurse | Charts | Stammdaten | Kennzahlen | Aktion |
---|---|---|---|---|
Snapshot | Preischart | Daten + Gebühr | Performance | Portfolio |
Börsenplätze | Performance | Management | Volatilität | Watchlist |
Historisch | Benchmark | Dokumente | Sharpe Ratio | |
Rendite | Ratings |
Kurse
Charts
Stammdaten
Kennzahlen
Anlageziel L&G Healthcare Breakthrough UCITS ETF
The investment objective of the Fund is to provide exposure to the global healthcare technology industry. In order to achieve this investment objective, the Fund will seek to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Stammdaten
Valor | |
ISIN | DE000A2PPAV6 |
Fondsgesellschaft | LGIM Managers |
Kategorie | Branchen: Gesundheitswesen |
Währung | USD |
VL-fähig? | Nein |
Thesaurierend/Ausschüttend | Thesaurierend |
Fondsmanager |
Aktuelle Daten
Aktueller Rücknahmepreis | 11.73 USD |
Fondsvolumen | 55’471’462.78 USD |
Total Expense Ratio (TER) | 0.49 % |
Gebühren
Verwaltungsgebühr | - |
Depotbankgebühr | - |
Rücknahmegebühr | - |
Ausgabeaufschlag | - |
Basisdaten
Auflagedatum | 26.06.2019 |
Depotbank | Bank of New York Mellon SA/NV, Dublin Branch |
Zahlstelle | |
Domizil | Ireland |
Geschäftsjahr | 30.06.2024 |
Performancedaten
Veränderung Vortag | 0.07 USD |